Spyre Therapeutics, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
Spyre is a preclinical-stage biotechnology company focused on next-generation antibody therapeutics for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The unaudited report covers the three months ended March 31, 2024, with comparison to March 31, 2023. The company has no commercially approved products and has not generated product revenue.
Lead programs include SPY001, an anti-α4β7 antibody, and SPY002, an anti-TL1A antibody. SPY003 and SPY004 remain discovery-stage programs, while combination programs are in preclinical development.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0.0 million | $0.2 million | Down 100% |
| Research and development expense | $34.9 million | $13.8 million | Up 154% |
| General and administrative expense | $12.8 million | $5.2 million | Up 146% |
| Total operating expenses | $47.8 million | $19.0 million | Up $28.8 million |
| Loss from operations | $47.8 million | $18.8 million | Worsened |
| Interest income | $4.4 million | $0.4 million | Up $4.0 million |
| Net loss | $43.9 million | $18.4 million | Worsened by $25.4 million |
| Basic and diluted loss per share | $1.20 | $4.89 | Improved per share due primarily to higher share count |
Margins are not meaningful because revenue was zero in Q1 2024. Research and development costs included $26.9 million for preclinical development and manufacturing activities, $5.4 million of stock-based compensation related to the Parapyre Option Obligation, and $17.1 million of related-party expenses associated with Paragon services.
At March 31, 2024, the company had $227.6 million of cash and cash equivalents, $257.1 million of marketable securities, and $0.3 million of restricted cash, totaling approximately $485.0 million in liquidity. Accumulated deficit was $808.3 million. The filing does not identify material conventional debt; liabilities primarily consisted of operating payables, accrued expenses, contingent value right liabilities, and related-party obligations.
| Cash flow | Q1 2024 | Q1 2023 |
|---|---|---|
| Cash used in operating activities | $28.5 million | $17.6 million |
| Cash used in investing activities | $105.0 million | Cash provided of $17.8 million |
| Cash provided by financing activities | $172.2 million | $0.01 million |
| Net increase in cash, cash equivalents and restricted cash | $38.7 million | $0.1 million |
Material Changes Versus the Prior Comparable Period
- Revenue ceased following termination of the Immedica license and supply agreement; Q1 2023 included $0.2 million of development fee revenue.
- Research and development spending increased substantially as Spyre advanced its IBD pipeline, while legacy rare-disease activities declined.
- External research and development costs increased to $31.3 million from $7.9 million, primarily reflecting IBD pipeline and Paragon-related activities.
- Stock-based compensation increased to $13.8 million from $1.7 million.
- The company raised $180.0 million in gross proceeds through the March 2024 private placement of Series B preferred stock, generating $169.2 million of net financing cash flow.
- Marketable securities increased to $257.1 million from $150.4 million, reflecting investment of financing proceeds.
- Series B preferred stock outstanding increased to 271,625 shares. The shares are convertible into common stock at a 40-to-1 ratio subject to ownership limitations and may be redeemable for cash if stockholder approval of conversion is not obtained.
Guidance, Outlook, Risks and Unusual Items
- Management states that existing cash, cash equivalents, and marketable securities are expected to fund operations for at least one year from the issuance date of the financial statements. Additional financing will be required to fund longer-term development and potential commercialization.
- SPY001’s first-in-human study was expected to begin in Q2 2024, subject to health agency approval, with interim healthy-volunteer data expected by year-end 2024.
- SPY002 was expected to enter a first-in-human study in the second half of 2024, with interim data expected in the first half of 2025, subject to additional preclinical work and regulatory approval.
- Management expects to nominate a SPY003 development candidate in mid-2024, begin IND-enabling studies in the second half of 2024, and potentially initiate first-in-human studies in the first half of 2025.
- Spyre had exercised its options for the SPY001 and SPY002 programs, but the related license agreements with Paragon had not yet been executed. Each agreement is expected to include a $1.5 million development-candidate fee, a $2.5 million first-dosing milestone, up to $22.0 million of additional development, regulatory, and clinical milestones, and royalties. SPY002 may also require up to approximately $20.0 million of sublicensing milestone payments.
- The contingent value right liability was $41.7 million at March 31, 2024. It relates to potential cash proceeds from monetization of legacy assets, including possible future payments from Immedica.
- Series B preferred stock had a stated redemption value of $412.1 million at March 31, 2024 if conversion approval is not obtained. The company expected to seek approval at its May 13, 2024 annual meeting.
- Related-party expenses payable to Paragon totaled $15.5 million at March 31, 2024. Fairmount, a significant stockholder and board-affiliated party, owns more than 5% of Paragon.
- The company remains exposed to clinical, regulatory, manufacturing, financing, intellectual property, and commercialization risks. No product candidate has been tested in humans as of the filing date.
- Subsequent to quarter-end, on April 25, 2024, Fairmount exchanged 90,992 Series A preferred shares for 3,639,680 common shares.
Important Facts for Investors to Verify
- Timing, regulatory clearance, enrollment, and results of the SPY001 and SPY002 first-in-human studies.
- Stockholder approval and ultimate conversion or cash redemption terms for the Series B preferred stock.
- Execution of the SPY001 and SPY002 license agreements and resulting milestone, royalty, and related-party payment obligations.
- Cash-burn rate, future financing requirements, and the period for which the reported $485.0 million liquidity balance will fund operations.
- Whether preclinical efficacy and half-life data translate into human safety, pharmacokinetic, and efficacy outcomes.
- Potential proceeds from legacy-asset monetization and the timing and amount of payments to CVR holders.
- Growth in stock-based compensation, Parapyre warrant obligations, and dilution from preferred stock, options, warrants, and other equity awards.